A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm.

Trial Profile

A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 May 2016

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders; Myocardial ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms R-US; RESOLUTE-US
  • Sponsors Medtronic
  • Most Recent Events

    • 21 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 31 Mar 2014 Results up to 4 years presented at the 63rd Annual Scientific Session of the American College of Cardiology.
    • 01 May 2011 The rationale and design of this study has been reported in American Heart Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top